Breakthrough in Quantum Measurement and Control System Technology (March, 2025)
Launched China’s first scalable low-latency feedback quantum control system ZW-QCS560 series, enabling “single-trigger multi-measurement” and rapid feedback control within 300 nanoseconds, solving critical quantum error correction challenges312.
News Link : https://finance.sina.com.cn/jjxw/2025-03-05/doc-inenprwv9366586.shtml
Related Posts
Antalpha Ventures, Web3Labs, and Goldford-HB Launch Computational Power Fund for AI and Web3 Projects
Antalpha Ventures, a global investment firm at the forefront of cutting-edge technology, has partnered with renowned Asian Web3 incubator Web3Labs and venture capital firm Goldford-HB to launch a new computational power fund. This fund aims to support early to mid-stage AI and Web3 projects worldwide by providing the necessary computational resources. Fund Back
Pillar Biosciences Closes $29.7 Million in Series C Financing
May 12, 2020NGS clinical cancer diagnostics company Pillar Biosciences held a Series C financing signing ceremony at its headquarters in Boston, USA, officially announcing the completion of a $29.7 million Series C financing round led by ORI Healthcare Fund, which raised Series A funding. The financing will accelerate the expansion of Pillar’s R&D pro
Based on the SIPS model ChangYi proposes marketing strategies for big health brands
According to the “Gen Z Nutrition Consumption Trend Report,” consumers aged 18-35 account for 83.7% of the total health and wellness market, becoming the main force driving growth. Driven by the “Healthy China” initiative and shifting health awareness, the industry is rapidly developing amid fierce competition. Marketing focus has shifte
Leto Laboratories Developing Semaglutide Biosimilar for Diabetes, Currently in Phase II Clinical Trial (2025)
Leto Laboratories is developing a Semaglutide biosimilar for diabetes and weight loss treatment, currently in Phase II clinical trials. The therapeutic candidate targets the GLP-1 receptor. According to GlobalData, Phase II diabetes drugs have a 38% success rate to advance to Phase III. Leto leverages its high-throughput screening and directional protein refold
Leave a Reply